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Potential Mechanisms for Cancer Resistance in Elephants and
Comparative Cellular Response to DNA Damage in Humans
Abstract
Importance: Evolutionary medicine may provide insights into human physiology and pathophysiology,
including tumor biology.
Objective: To identify mechanisms for cancer resistance in elephants and compare cellular response to DNA
damage among elephants, healthy human controls, and cancer-prone patients with Li-Fraumeni syndrome
(LFS).
Design, Setting, and Participants: A comprehensive survey of necropsy data was performed across 36
mammalian species to validate cancer resistance in large and long-lived organisms, including elephants (n =
644). The African and Asian elephant genomes were analyzed for potential mechanisms of cancer resistance.
Peripheral blood lymphocytes from elephants, healthy human controls, and patients with LFS were tested in
vitro in the laboratory for DNA damage response. The study included African and Asian elephants (n = 8),
patients with LFS (n = 10), and age-matched human controls (n = 11). Human samples were collected at the
University of Utah between June 2014 and July 2015.
Exposures: Ionizing radiation and doxorubicin.
Main Outcomes and Measures: Cancer mortality across species was calculated and compared by body size
and life span. The elephant genome was investigated for alterations in cancer-related genes. DNA repair and
apoptosis were compared in elephant vs human peripheral blood lymphocytes.
Results: Across mammals, cancer mortality did not increase with body size and/or maximum life span (eg,
for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%]; lion, 2% [95% CI, 0%-7%]).
Despite their large body size and long life span, elephants remain cancer resistant, with an estimated cancer
mortality of 4.81% (95% CI, 3.14%-6.49%), compared with humans, who have 11% to 25% cancer mortality.
While humans have 1 copy (2 alleles) of TP53, African elephants have at least 20 copies (40 alleles), including
19 retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse transcription
polymerase chain reaction. In response to DNA damage, elephant lymphocytes underwent p53-mediated
apoptosis at higher rates than human lymphocytes proportional to TP53 status (ionizing radiation exposure:
patients with LFS, 2.71% [95% CI, 1.93%-3.48%] vs human controls, 7.17% [95% CI, 5.91%-8.44%] vs
elephants, 14.64% [95% CI, 10.91%-18.37%]; P < .001; doxorubicin exposure: human controls, 8.10% [95%
CI, 6.55%-9.66%] vs elephants, 24.77% [95% CI, 23.0%-26.53%]; P < .001).
Conclusions and Relevance: Compared with other mammalian species, elephants appeared to have a lower-
than-expected rate of cancer, potentially related to multiple copies of TP53. Compared with human cells,
elephant cells demonstrated increased apoptotic response following DNA damage. These findings, if
replicated, could represent an evolutionary-based approach for understanding mechanisms related to cancer
suppression.
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Srividya Bhaskara, PhD; Shane T. Jensen, PhD; Carlo C. Maley, PhD; Joshua D. Schiffman, MD
IMPORTANCE Evolutionary medicine may provide insights into human physiology and
pathophysiology, including tumor biology.
OBJECTIVE To identify mechanisms for cancer resistance in elephants and compare cellular
response to DNA damage among elephants, healthy human controls, and cancer-prone
patients with Li-Fraumeni syndrome (LFS).
DESIGN, SETTING, AND PARTICIPANTS A comprehensive survey of necropsy data was
performed across 36mammalian species to validate cancer resistance in large and long-lived
organisms, including elephants (n = 644). The African and Asian elephant genomes were
analyzed for potential mechanisms of cancer resistance. Peripheral blood lymphocytes from
elephants, healthy human controls, and patients with LFS were tested in vitro in the
laboratory for DNA damage response. The study included African and Asian elephants
(n = 8), patients with LFS (n = 10), and age-matched human controls (n = 11). Human samples
were collected at the University of Utah between June 2014 and July 2015.
EXPOSURES Ionizing radiation and doxorubicin.
MAIN OUTCOMES ANDMEASURES Cancermortality across species was calculated and
compared by body size and life span. The elephant genomewas investigated for alterations in
cancer-related genes. DNA repair and apoptosis were compared in elephant vs human
peripheral blood lymphocytes.
RESULTS Across mammals, cancer mortality did not increase with body size and/or maximum
life span (eg, for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%];
lion, 2% [95% CI, 0%-7%]). Despite their large body size and long life span, elephants remain
cancer resistant, with an estimated cancer mortality of 4.81% (95% CI, 3.14%-6.49%),
compared with humans, who have 11% to 25% cancer mortality. While humans have 1 copy
(2 alleles) of TP53, African elephants have at least 20 copies (40 alleles), including 19
retrogenes (38 alleles) with evidence of transcriptional activity measured by reverse
transcription polymerase chain reaction. In response to DNA damage, elephant lymphocytes
underwent p53-mediated apoptosis at higher rates than human lymphocytes proportional to
TP53 status (ionizing radiation exposure: patients with LFS, 2.71% [95% CI, 1.93%-3.48%] vs
human controls, 7.17% [95% CI, 5.91%-8.44%] vs elephants, 14.64% [95% CI,
10.91%-18.37%]; P < .001; doxorubicin exposure: human controls, 8.10% [95% CI,
6.55%-9.66%] vs elephants, 24.77% [95% CI, 23.0%-26.53%]; P < .001).
CONCLUSIONS AND RELEVANCE Comparedwith othermammalian species, elephants
appeared to have a lower-than-expected rate of cancer, potentially related tomultiple copies
of TP53. Compared with human cells, elephant cells demonstrated increased apoptotic
response following DNA damage. These findings, if replicated, could represent an
evolutionary-based approach for understandingmechanisms related to cancer suppression.
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T he mechanisms that prevent accumulation of geneticdamage and subsequent uncontrolled proliferationof somatic cells in multicellular organisms remain
poorly understood. A greater number of cells and cell divi-
sions increases the chance of accumulating mutations result-
ing in malignant transformation.1 If all mammalian cells are
equally susceptible to
oncogenic mutations,
then cancer risk should
increase with body size
(number of cells) and
species life span (number
of cell divisions). The
Peto paradox describes
the observation that cancer incidence across animals does
not appear to increase as theoretically expected for larger
body size and life span.2,3 To our knowledge, the cellular
mechanism for this phenomenon of cancer resistance has
never been demonstrated experimentally in organisms other
than rodents.4-6
TP53 (encoding the protein p53 [RefSeq NM_000546]) is
a crucial tumor suppressor gene, mutated in the majority of
human cancers.7 Referred to as the “guardian of the
genome,” inactivation of p53 leads to 3 cancer cell character-
istics including suppression of apoptosis, increased prolifera-
tion, and genomic instability.8,9 Humans contain 1 copy
(2 alleles) of TP53, and both functioning alleles are crucial to
prevent cancer development. Absence of 1 functional allele
leads to Li-Fraumeni syndrome (LFS), a cancer predisposi-
tion with more than a 90% lifetime risk for cancer, multiple
primary tumors, and early childhood cancers.10,11 Under-
standing the cellular mechanism of cancer suppression in
animals could benefit humans at high risk of cancer, such as
patients with LFS, and even the healthy, aging population.
This study investigated the cancer rate in differentmam-
mals (including elephants), identified potential molecular
mechanisms of cancer resistance, and compared response to
DNA damage in elephants with that in healthy human con-
trols and individuals with LFS.
Methods
Ethical and scientific institutional reviewboard approvalwas
obtained fromeachparticipating research organization for all
elephant and human participation, including written in-
formed consent fromhuman participants. Experiments were
performed on peripheral blood lymphocytes (PBLs) from
African and Asian elephants, from a representative clinical
cohort of patients with LFS enrolled in a separate study (the
Cancer Genetics Study, University of Utah), and from age-
matched human controls without a significant family history
of cancer also enrolled in the Cancer Genetics Study. Patients
withLFSwere selected for inclusionasa representative sample
basedonTP53mutationstatus,variedcancerhistory,andavail-
ability for blood draw. Human subject materials were col-
lected at the University of Utah from June 2014 to July 2015.
Laboratory experiments were also performed on African
elephant fibroblasts, human fibroblasts, and HEK293 cells to
confirm these findings.
Necropsy data were examined from zoo animals to
determine if empirical evidence supports that cancer inci-
dence does not increase with body size or life span. Fourteen
years of necropsy data collected by the San Diego Zoo12 was
compiled and tumor incidence was calculated for 36 mam-
malian species, spanning up to 6 orders of magnitude in size
and life span.13 Data from the Elephant Encyclopedia14 were
analyzed on the cause of death in captive African (Loxodonta
africana) and Asian (Elephas maximus) elephants to estimate
age incidence and overall lifetime cancer risk. Using the
cancer transformation model from Calabrese and Shibata,15
the percentage decrease in cellular mutation rate was calcu-
lated to account for a 100× increase in cell mass (the differ-
ence between elephants and humans) without cancer
development.
Genomic sequence analysis was next performed on the
publicly available scaffolds of theAfrican elephant genome in
the Ensembl database (release 72; http://www.enssemble
.org/) and the NCBI Gene database (http://www.ncbi.nlm.nih
.gov/gene), with examination of cancer-related genes includ-
ing oncogenes and tumor suppressors. TP53 sequence
alignmentswere explored in related species, and African and
Asian elephant TP53 retrogenes were cloned and rese-
quenced. Capillary sequencing was performed on single el-
ephants to avoid issues of single-nucleotide polymorphisms
betweenelephants.Wholegenomesequencing (IlluminaHiSeq
2500)wasperformedonfreshlyextractedDNAfromanAfrican
elephant at 40× average sequence coverage, with more than
100× coverage within areas of TP53.
Functional molecular analysis of TP53 and its retrogenes
was performed on peripheral blood mononuclear cells from
African and Asian elephants and fibroblasts from an African
elephant. To determine if TP53 retrogenes are expressed in
the elephant, reverse transcription–polymerase chain reac-
tion was performed on RNA collected from African elephant
peripheral blood mononuclear cells and African elephant
fibroblasts. Polymerase chain reaction primers were
designed to distinguish the TP53 retrogenes from the ances-
tral sequence and splice variants. Human vs elephant DNA
repair efficiency (measured by double-strand breaks indi-
cated by number of phospho-histone H2AX [pH2AX] foci),
apoptosis (annexin V [AV] and propidium iodide [PI] by flow
cytometry and Apotox-Glo, Promega), and cell cycle arrest
(Apotox-Glo, Promega) were compared at different time
points (1, 5, 10, 18, 24, and 72 hours) after DNA damage
(doxorubicin, 0.005-30 μM; and ionizing irradiation, 0.5, 2,
5, 6, 10, and 20 Gy). Late apoptosis was defined as AV+PI+
and early apoptosis was defined as AV+PI−. Experiments
were performed in either triplicate or quadruplicate. p53
plays a critical role in p21 andmouse double minute 2 homo-
log (Mdm2 or E3 ubiquitin-protein ligase Mdm2) protein
induction following DNA damage,16,17 so p21 immunoblots
were performed to validate a p53-dependent DNA damage
response in elephant cells. p53 retrogene 9 (GenBank
KF715863) was cloned into an expression vector to produce a
protein fused to an epitope from the Myc protein. HEK293
AV annexin V
LFS Li-Fraumeni syndrome
Mdm2 mouse double minute
2 homolog
PBL peripheral blood lymphocyte
PI propidium iodide
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cells were transfected with this Myc-tagged p53 retrogene 9
expression vector and p53 retrogene protein expression was
measured by immunoblot using an antibody to the Myc tag.
Retrogene protein product was co-immunoprecipitated from
HEK293 cell lysates with Myc antibody, followed by immu-
noblots for phospho-p53 (serine-15) and Mdm2. The HEK293
cell line was chosen for these experiments because it is a
human cell line (human embryonic kidney) that is easy to
transfect and measure protein expression.
Cross-species lifetime cancer incidencewas estimated by
the number of animals in each species that reportedly died of
cancer.A logistic regressionmodelwas fit todetermine if body
massandmaximumlife spanarevariablesassociatedwithcan-
cer incidence (R software, version3.2.1). Additionally, all com-
binations of mass, life span, and mass-specific basal meta-
bolic rate were examined for evidence of cancer association.
An inversecancerassociationwasspecifically tested in the larg-
est existing terrestrial mammal, the elephant. For the DNA
damage analysis, a χ2 test was used to compare pH2AX foci,
and anunpaired 2-sided t testwith α = .05wasused for apop-
tosis andcell cycle arrest (R software, version3.2.1, andGraph-
PadPrism, version6.0e). Both a linear regression anda Jonck-
heere-Terpstra test were used to assess if apoptotic response
decreased with age.
Details of the experimental methods are further de-
scribed in the eAppendix in the Supplement.
Results
Zoo Necropsies and CancerMortality
The 36 mammalian species analyzed spanned from the
striped grass mouse (weight, 51 g, with a maximum life span
of 4.5 years) to the elephant (weight, 4800 kg, with a maxi-
mum life span of 65 years). Cancer risk did not increase with
mammalian body size and maximum life span among 36
species analyzed (eg, for rock hyrax, 1% [95% CI, 0%-5%];
African wild dog, 8% [95% CI, 0%-16%]; lion, 2% [95% CI,
0%-7%]) (Figure 1). No significant relationship was found
with any combinations of mass, life span, and basal meta-
bolic rate and cancer incidence (eFigure 1 and eTable 1 in the
Supplement). Among 644 annotated elephant deaths
from the Elephant Encyclopedia database, the lifetime
cancer incidence was 3.11% (95% CI, 1.74%-4.47%) (Table 1).
To obtain a more conservative estimate, an inferred cancer
incidence was calculated for cases that lacked adequate
details for the cause of death, leading to an estimated
elephant cancer mortality rate of 4.81% (95% CI, 3.14%-
6.49%). Based on an algebraic model of carcinogenesis,15
a 2.17-fold decrease in mutation rate was calculated as
sufficient to protect elephants from cancer development
given their 100× increased cellular mass compared with
humans.
Figure 1. Cancer Incidence Across Species by Body Size and Life Span
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Themammalian species studied span the striped grass mouse to the elephant.
Cancer incidence is not associated with mass and life span, as shown by the
logistic regression (model fit shown as blue line; 95% CIs shown as dashed
lines). Each data point in the graph is supported by aminimum of 10 necropsies
for the includedmammals (San Diego Zoo) and 644 annotated deaths for
elephants (Elephant Encyclopedia database). The risk of cancer depends on
both the number of cells in the body and the number of years over which those
cells can accumulate mutations; therefore, cancer incidence is plotted as a
function of mass × life span. All data with 95% CIs are presented in eTable 1 in
the Supplement.
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African Elephant GenomeAnalysis
The African elephant (L africana) draft genome LoxAfr3 con-
tains 19 copies of TP53. The human haploid genome con-
tains 1 copy of TP53,while Ensembl and GenBank annotate a
large number of TP53 paralogs in the African elephant
genome (12 and 20 haploid copies, respectively; eTable 2 in
the Supplement). Elephant sequence alignments revealed 1
TP53 copy with a comparable gene structure to TP53 found
in other mammalian species (ancestral copy). The other 19
copies lack true introns, suggesting that they originated
from retrotransposition (retrogenes). Cloning and rese-
quencing confirmed at least 18 distinct retrogene copies in
the African elephant in a maximum likelihood phylogeny,
supported by multiple clones clustered into 2 main subtrees
(groups A and B; Figure 2). Whole-genome sequencing with
deep coverage confirmed 1 ancestral copy and 19 total retro-
gene copies, similar to the TP53 20 total copies annotated in
GenBank. Eleven of the 18 retrogenes from the capillary
sequencing were similar but not identical to previous Gen-
Bank annotations and local whole genome sequencing data
(eTable 2 in the Supplement). High variance in coverage
across reference TP53 copies may indicate additional TP53
elephant copies not yet successfully assembled. There was
no evidence for 8 of the published retrogene copies, possibly
because of undersampling of clones, misassembly in the
published genome, or differences between individual
elephants. An additional 7 cloned sequences had support
from multiple clones but were not found in either database.
Further TP53 copies in the genome may also have been
undetected by the polymerase chain reaction primers. The
Asian elephant DNA was also found to contain 15 to 20 cop-
ies of group A and B TP53 retrogenes (eFigure 2 in the
Supplement).
TP53 Retrogene Transcription and Translation
Reverse transcription–polymerase chain reaction on RNA
from African elephant peripheral blood mononuclear cells
and fibroblasts exposed to 2 Gy of radiation demonstrated
TP53 retrogene expression. Products of the expected sizes
were observed, separating the 2 groups of retrogenes (eFig-
ure 3 in the Supplement). Sanger sequencing confirmed their
identities as retrogenes from group A and/or group B (eFigure
4 in the Supplement). Transfected HEK293 cells showed p53
retrogene 9 protein expression by immunoblotting that
increased with DNA damage similar to p53 in human fibro-
blasts exposed to DNA damage (eFigure 5, A-B, in the Supple-
ment). Co-immunoprecipitation of lysates from the trans-
fected HEK293 cells exposed to 6 Gy of ionizing radiation
displayed phosphorylation of the Myc-tagged p53 elephant
retrogene at serine-15 along with 90 kDa Mdm2, indicating
Mdm2 binding (eFigure 5C in the Supplement).
Elephant Cell Response to DNADamage
Lymphocytes undergo p53-dependent apoptosis in response
to DNA damage,18,19 while fibroblasts undergo both p53-
dependent apoptosis and cell cycle arrest,20-22 and both
elephant cell types were tested accordingly. African elephant
PBLs demonstrated apoptosis at significantly elevated rates
compared with human PBLs after 18 hours when exposed to
2 Gy of ionizing radiation (late apoptosis: 33.20% [95% CI,
28.31%-38.09%] vs 14.07% [95% CI, 13.13%-15.01%];
P < .001; early apoptosis: 21.07% [95% CI, 19.61%-22.52%] vs
11.73% [95% CI, 11.35%-12.11%]; P < .001) (Figure 3, A-C) and
when exposed to 5 μM of doxorubicin (24.77% [95% CI,
23.0%-26.53%] vs 8.10% [95% CI, 6.55%-9.66%]; P < .001)
(eFigure 6 in the Supplement). Peripheral blood lympho-
cytes from individuals with LFS (n = 10), healthy controls
(n = 10), and 1 African elephant (tested in 3 independent
experiments) treated with 2 Gy of ionizing radiation revealed
different levels of apoptosis (apoptosis calculated at 18 hours
by subtracting the percentage of AV+PI+ cells treated with 2
Gy of ionizing radiation from the percentage of AV+PI+ cells
cultured without treatment). Cells of patients with LFS
underwent significantly less apoptosis (2.71%; 95% CI,
1.93%-3.48%) compared with healthy human PBLs (7.17%;
95% CI, 5.91%-8.44%; P < .001) and elephant PBLs (14.64%;
95% CI, 10.91%-18.37%; P < .001) (Figure 4 and eTable 3 in
the Supplement).
No significant difference was detected in pH2AX foci
following ionizing radiation between human and elephant
Table 1. Cause of Death in 644 Elephantsa
Age
Range, y
Total
Necropsies
No. of Elephants
Observed % With
Cancer (95% CI)
Inferred % With
Cancer (95% CI)
Euthanized,
Noncancer
Noncancer
Disease
Exogenous
Mortality
Euthanized,
Unspecified
Disease,
Unspecified
Euthanized,
Cancer
Cancer
0-5 125 15 77 28 1 2 0 2 1.60 (0.00-4.24) 2.40 (0.00-5.44)
6-15 83 20 36 19 4 1 1 2 3.61 (0.00-8.02) 6.02 (0.58-11.47)
16-25 121 35 48 25 7 2 2 2 3.31 (0.00-6.69) 4.96 (0.86-9.05)
26-35 108 27 51 15 8 4 3 0 2.78 (0.00-6.11) 3.70 (0.00-7.60)
36-45 94 32 27 13 12 5 0 5 5.32 (0.47-10.16) 6.38 (1.18-11.58)
46-55 70 14 23 7 7 17 1 1 2.86 (0.00-7.37) 5.71 (0.00-11.59)
≥56 43 3 7 6 7 19 1 0 2.33 (0.00-8.16) 6.98 (0.00-15.29)
Lifetime,
0-≥56
644 146 269 113 46 50 8 12 3.11 (1.74-4.47) 4.81 (3.14-6.49)
a Observed cancers are reported as the percentage of deaths annotated as
being caused by cancer or by euthanasia due to cancer. Inferred cancer risk
assumes that cancer occurs at the same fraction of deaths in cases with
unspecified causes as those with specified causes. Exogenous causes of
mortality include accidents (eg, falling in the enclosure) and animal fights that
cause fatal injury.
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Figure 2. Group A and Group B TP53 Retrogenes in the African Elephant
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Amaximum likelihood phylogeny was used to cluster the sequenced TP53
retrogene clones and to confirm the number of unique genes uncovered in the
African elephant genome. The phylogeny allows for visualization of TP53
retrogene similarity to one another as well as their relationship to the ancestral
TP53 sequence in the elephant and hyrax. The capillary sequenced clones from
this study are shown as black circles and published sequences from GenBank
are shown as red squares. Gene identifiers and genomic coordinates are given in
eTable 2 in the Supplement. Phylogenic analysis reveals at least 18 distinct
clusters of processed TP53 copies (shown as colored blocks numbered 1 to 18).
These clusters fall into 2 groups, labeled group A and group B. The branch
labeled “elephant” is the coding sequence of the ancestral TP53, and “hyrax”
represents the coding sequences from the hyrax TP53. The hyrax, on the upper
left, is used as the outgroup to show that the hyrax and elephant ancestral TP53
sequences are more similar to each other than to the retrogenes, and also that
the retrogenes evolved after the split between hyrax and elephant. The
distances between the retrogene sequences display their relationship based on
sequence similarity but do not represent precise evolutionary time estimates.
These data were generated with DNA from 1 elephant to control for
polymorphic bases between individual elephants.
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PBLs, indicating that the increased apoptosis in elephants
cannot be attributed to more DNA damage (Table 2,
Figure 5, and eFigure 7 in the Supplement). This increased
apoptosis was observed in different lymphocyte wash con-
ditions (eFigure 8 in the Supplement). Unlike increasing
TP53 mRNA levels seen in human PBLs after ionizing radia-
Figure 3. African Elephant and Human Peripheral Blood Lymphocytes and Sensitivity to Ionizing Radiation
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A, The percentage of late apoptosis
(annexin V positive [AV+] and
propidium iodide positive [PI+]) and
B, early apoptosis (AV+PI−) in
elephant peripheral blood
lymphocytes compared with human
peripheral blood lymphocytes in
response to 2 Gy and 6 Gy of ionizing
radiation are graphed. Significant
differences computed with a 2-sided
t test between human and elephant
at 0, 5, 10, 18, and 24 hours are
indicated. Error bars represent 95%
CIs. C, Representative scatter plots
from flow cytometry are shown from
the 0- and 18-hour time points. NT
indicates no treatment.
a P < .001.
b Panel A: NT at 10 hours, P = .008.
Panel B: NT at 0 hours, P = .002;
2 Gy at 5 hours, P = .003; 6 Gy at
5 hours, P = .004.
c P = .03.
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tion, gene expression of ancestral and retrogene TP53 did
not increase in elephant PBLs (eFigure 9 in the Supple-
ment). Both elephant and human PBLs showed p53 and p21
protein expression following ionizing radiation exposure
(Figure 6). More p21 protein expression was observed at 5
hours in elephant PBLs treated with 0.5 Gy of ionizing radia-
tion (20.1-fold increase; 95% CI, 8.72- to 31.5-fold) com-
pared with human PBLs (3.5-fold increase; 95% CI, 1.7- to
5.31-fold; P = .004) (eFigure 10, A-B, in the Supplement).
Elephant fibroblasts also showed increased p21 protein
expression following 2 Gy of ionizing radiation at 5 hours
(1.9-fold increase) compared with no increase in human
fibroblasts (eFigure 10C in the Supplement). Similar to lym-
phocytes, elephant vs human fibroblasts showed evidence
of increased apoptosis after 10 μM of doxorubicin as mea-
sured by increased caspase activity relative to dimethyl
sulfoxide–treated fibroblasts (elephant: 9.1-fold increase
[95% CI, 7.93- to 10.25-fold] vs human: 2.24-fold increase
[95% CI, 1.5- to 2.98-fold]; P < .001) and additionally
showed reduced viability consistent with cell cycle
arrest after 0.5 Gy of ionizing radiation (elephant: 80.81%
[95% CI, 68.86%-92.75%] vs human: 95.87% [95% CI,
90.73%-101.0%]; P = .01) (eFigure 11 in the Supplement;
some of the elephant fibroblast experiments do not
have P values because they were designed to demonstrate
p21 protein expression and not powered for statistical
comparison).
As a post hoc analysis, the same experiments were re-
peated in PBLs from multiple Asian elephants (n = 6) of dif-
ferent ages (2, 12, 17, 38, 57, and 69 years old). Asian elephant
lymphocytes also demonstrated an increased rate of apopto-
sis (50.63%; 95% CI, 41.71%-59.53%) relative to human cells
(23.67%; 95%CI, 21.18%-26.15%;P < .001)when exposed to 2
Gy of ionizing radiation (18-hour culture) and an increase in
p21 expression (Figure 7, A-B). Additionally, the apoptotic re-
sponse inPBLsdecreasedwith theageofAsianelephantswhen
tested with both a linear regression and a Jonckheere-
Terpstra test, which allows for nonlinear relationships
(Figure7C) (2-year-oldelephantwith2Gyradiationat 18hours,
52.53% [95% CI, 35.86%-69.2%] and 69-year-old elephant,
40.03% [95% CI, 30.64%-49.43%]; P = .002 by linear regres-
sion; P < .001 by Jonckheere-Terpstra test). These age-
related results should be interpreted as exploratory and hy-
pothesis generating.
Discussion
Peto first made the observation more than 35 years ago that
larger and longer-lived mammals develop less cancer than
expected,3,23,24 but the evolutionary and functional mecha-
nisms for this phenomenon have been studied only in
rodents.4-6 To our knowledge, this study offers the first sup-
porting evidence based on empirical data that larger animals
with longer life spans may develop less cancer, especially
elephants. The cancer mortality rate for elephants was found
Figure 4. Apoptosis Response Relative to Number of Copies of TP53
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1 African elephant tested in 3 independent experiments (with 40 TP53 alleles).
Ionizing radiation–induced apoptosis increased proportionally with additional
copies of TP53 and inversely correlated with cancer risk. Experiments
performed in quadruplicate for each individual and each colored box represents
themean percentage of cells in late apoptosis as measured by flow cytometry
(percentage of annexin V–positive [AV+] and propidium iodide–positive [PI+]
treated cells minus AV+PI+ untreated cells). The healthy control lymphocytes
underwent more apoptosis than those from LFS patients (P < .001),
and elephant lymphocytes underwent more apoptosis than those from
healthy controls (P < .001 by 2-sided t test). Horizontal lines indicate
the combinedmean for all data points in each group with error bars
indicating 95% CIs.
Table 2. pH2AX Foci in Human and African Elephant Cells After 2 Gy of Ionizing Radiationa
Treatment and Time Frame
Viable Cells With Indicated No. of pH2AX Foci, %
0-5 Foci 6-10 Foci 11-15 Foci 16-≥20 Foci
Human Elephant Human Elephant Human Elephant Human Elephant
No treatment, 1 h 97.3 98.7 2.7 1.3 0.0 0.0 0.0 0.0
No treatment, 5 h 97.7 98.0 2.3 1.3 0.0 0.7 0.0 0.0
No treatment, 24 h 99.7 99.7 0.3 0.3 0.0 0.0 0.0 0.0
2 Gy, 1 h 23.0 26.3 25.3 33.7 19.0 17.0 32.7 23.0
2 Gy, 5 h 46.7 51.0 32.7 39.0 14.3 9.0 6.3 1.0
2 Gy, 24 h 94.3 92.3 5.3 7.3 0.3 0.0 0.0 0.0
a Foci indicate remaining DNA double-stranded breaks. Cells are binned by the
number of phospho-histone H2AX (pH2AX) foci and demonstrate no
significant difference in the rate of DNA damage repair between human and
elephant (P > .05 by χ2 test).
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to be less than 5% compared with a cancer mortality rate for
humans of 11% to 25%.25 Additionally, TP53 amplification
was identified in elephants, and the effect TP53 amplification
may have on apoptotic response to DNA damage was
explored. These findings support the concept of an
evolutionary-based approach for cancer suppression.
TP53 plays a central role in cancer suppression and
response to DNA damage through apoptosis and cell cycle
arrest.8,26,27 Patients with LFS inherit only 1 functioning
TP53 allele and may have a lifetime risk of cancer approach-
ing 100%.10,11 Conversely, inserting additional copies of con-
stitutively active TP53 in mice confers cancer resistance
with accelerated aging,28 while redundant TP53 alleles
under the endogenous promoter generate cancer-resistant
laboratory mice that age normally.29 The evolution of the
elephant would have involved a strong selective pressure to
naturally suppress cancer in a long-lived animal 100 000
times the size of a mouse. Female elephants reproduce and
raise offspring throughout their entire life span of 50 to 80
years, older males have higher status andmore reproductive
opportunities,30 and herds with older matriarchs may have
higher fitness.31 The enormous mass, extended life span,
and reproductive advantage of older elephants would have
selected for an efficient and fail-safe method for cancer sup-
pression. The multiple copies of TP53 and the enhanced
p53-mediated apoptosis observed in elephants may have
evolved to offer such cancer protection.
The data suggest a lower threshold for DNA damage
before triggering p53-dependent apoptosis in elephants than
in humans, a possible evolutionary strategy to avoid cancer
by efficiently removing mutant cells. Consistent with previ-
ous evidence that increasing TP53 gene dosage increases
Figure 6. p21 and p53 Protein Expression After Ionizing Radiation
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Figure 5. Visualization of Apoptosis and DNADamage in Human and Elephant Cells After Ionizing Radiation
African elephant PBLs 5 h after 2 Gy ionizing radiationA Human PBLs 5 h after 2 Gy ionizing radiationB
DAPI, a nuclear stain that binds to
DNA (blue), and phospho-histone
H2AX foci (green) labeled peripheral
blood lymphocytes (PBLs) 5 hours
after 2 Gy of ionizing radiation show
similar amounts of DNA damage.
Apoptosis, rarely observed in the
human cells, is visualized in the
elephant cells (blue arrowheads
indicate apoptotic cells with DNA
fragmentation, identified by nuclear
blebbing). Images displayed at
40×magnification.
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transcriptional regulation of p53 target genes,17,27 apoptotic
rates in lymphocytes increased proportionally among
patients with LFS (1 TP53 functioning allele), human controls
(2 TP53 alleles), and elephants (40 TP53 alleles). Elephant
cells exposed to DNA damage showed increased p21 expres-
sion, a downstream target of p53 activation. Also, p53 retro-
genes were up-regulated and translated when transfected
into human cells treated with ionizing radiation and doxoru-
bicin. These combined observations suggest that the
increased cell death in elephants may be mediated by p53
and enhanced by the additional TP53 retrogenes.
Retrotransposed genes, often called pseudogenes, can
play functional roles in biology.32,33 Based on the study
results, the TP53 retrogenes may functionally increase
elephant cell response to DNA damage by triggering p53-
dependent apoptosis rather than increasing DNA repair.
Apoptosis can prevent mutations from propagating to
future cell generations through removal of mutated clones.
The elephant cells appeared twice as sensitive to DNA
damage–induced apoptosis as human cells. Increasing
apoptosis effectively lowers the ongoing mutation rate for
the entire cell population and, as calculated, this 2-fold
decrease in the somatic mutation rate (doubling of apopto-
sis) in elephants could explain the 100× increase in cell
mass without cancer transformation.15,34 The Asian
elephant genome contained 15 to 20 TP53 retrogene copies,
suggesting that TP53 retrogene amplification predated the
split of the African and Asian elephant species approxi-
mately 6.6 million to 8.8 million years ago.35 The hyrax
(Procavia capensis) is the closest elephant relative with an
available genome assembly (proCap1) and contains only 1
copy (2 alleles) of TP53. The hyrax and elephant lineages
diverged 54 million to 65 million years ago,36 making this
time frame the upper bound of when these TP53 retrogenes
evolved.
A consistent age-related decrease in apoptosis was found
inAsian elephants. Age-related decline in apoptotic response
has beenobserved inmurineT cells,37 humanPBLs,38 andhu-
man sperm.39 Young elephants rapidly grow in less than 10
years from a birth weight of 100 kg to more than 3000 kg at
reproductiveage, a 30-fold increase in cellularmasswithmore
than 1 kg of weight gain per day. Such a high rate of cell divi-
sion and expansion in the growing elephant requires an espe-
cially efficient system of cancer prevention.
The study of cancer and apoptosis across species has
several limitations. Cancer mortality rates in humans are
often reported as deaths per 100 000 per year,25 and suffi-
cient sample sizes of animals are difficult to find for com-
parison. The cross-species mortality rates in this study
included estimates based on small numbers of captive ani-
mals with wide confidence intervals. More data need to be
collected to confidently demonstrate the absence of correla-
tion of mass and life span with cancer mortality. Environ-
mental factors also play a role in cancer development, and it
is unclear how captivity influences cancer rates through
diet, stress, physical activity, and reproduction. The
expected life span of captive African and Asian elephants is
decreased,40 and this analysis may not have fully captured
the elderly elephant population most expected to develop
cancer. Adding to the complexity, humans are treated with
modern medicine and may have an artificially extended life
span, which, along with carcinogenic exposures like smok-
ing, increases the lifetime risk of cancer death. Neither the
African nor Asian elephant genome has been formally
assembled and, consequently, elephant-specific molecular
agents such as phosphorylated p53 elephant antibodies to
measure elephant p53 activation are challenging to obtain.
Studying the p53 pathway requires certain assumptions,
such as that p21 and Mdm2 protein levels truly reflect p53
activity, as they do in humans. Although the data are sug-
Figure 7. Asian Elephant Cells and DNADamage Response
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gestive, it is still unknown if elephant TP53 retrogenes pro-
duce functional protein. These retrogenes may serve as
either functional or nonfunctional protein decoys for degra-
dation (eFigure 12 in the Supplement), explaining the
co-immunoprecipitation of Mdm2 with TP53 elephant ret-
rogenes. With further assembly of the elephant genome,
future experiments with genomic technologies like RNA
sequencing will prove helpful in understanding the func-
tional differences reflected in the increased apoptosis found
in elephants.
Conclusions
Compared with other mammalian species, elephants ap-
peared to have a lower-than-expected rate of cancer, poten-
tially related to multiple copies of TP53. Compared with hu-
man cells, elephant cells demonstrated increased apoptotic
response following DNA damage. These findings, if repli-
cated, could represent anevolutionary-basedapproach forun-
derstanding mechanisms related to cancer suppression.
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